Innocan Pharma management commentary cites lower online sales as revenue falls to US$11.72 million in H1 2026
Reuters2026/08/31 20:33- In management commentary for the three and six months ended June 30, 2026, revenue fell to USD 11.72 million from USD 14.8 million.
- Lower online sales volumes drove the decline, reflecting challenging market conditions despite portfolio and marketing initiatives.
- Gross profit margin rose 1.2% for the six-month period, attributed to supply-chain optimization and cost savings.
- Net loss widened to USD 1.04 million from USD 544,000, reflecting weaker revenue and higher general and administrative expense.
- Cash was USD 6.4 million; working capital was USD 8.38 million, down from USD 9.47 million at year-end.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Global bond market sell-off intensifies! Australian bond yields hit a fifteen-year high as traders bet on Reserve Bank of Australia resuming rate hikes soon
Due to intensified global sovereign bond sell-offs and domestic inflation and consumption data continuously exceeding expectations, Australia’s benchmark government bond yield has risen to its highest level since 2011.
Japan’s MOF official says expects BoJ to steer policy aligned with economy, not influenced by US
2-Yr Benchmark Govt Yields - Germany vs Other Nations
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
